Health Canada delays drug-pricing reforms, citing COVID-19 challenges for manufacturers Adina Bresge Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Graeme Roy/The Canadian Press
Health Canada says it’s delaying its long-awaited overhaul of drug-pricing regulations by another six months.
While pharmaceutical manufacturers and patient advocates welcomed the decision, they say the federal government needs to go back to the drawing board for Canada to stay competitive in the global marketplace for medical innovation.